Financials in USD. Standardized financial statements.
A compact view of how BioNTech SE turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.76B | $2.75B | $3.82B | $17.31B | $18.98B | $482.30M | $108.60M | $127.58M | $61.60M |
| Revenue Growth? | +0.2% | -28.0% | -77.9% | -8.8% | +3834.6% | +344.1% | -14.9% | +107.1% | 0.0% |
| Cost of Revenue? | $616.47M | $541.30M | $599.80M | $3.00B | $2.91B | $59.30M | $17.40M | $13.69M | $9.32M |
| Gross Profit? | $2.14B | $2.21B | $3.22B | $14.32B | $16.07B | $423.00M | $91.20M | $113.89M | $52.28M |
| Gross Margin? | +77.6% | +80.3% | +84.3% | +82.7% | +84.7% | +87.7% | +84.0% | +89.3% | +84.9% |
| Operating Expenses? | $2.76B | $3.52B | $2.53B | $1.67B | $781.40M | $505.40M | $272.70M | $167.74M | $113.56M |
| Operating Income? | -$623.87M | -$1.31B | $690.40M | $12.64B | $15.28B | -$82.40M | -$181.50M | -$53.85M | -$61.28M |
| EBITDA? | -$256.17M | -$367.10M | $1.38B | $13.10B | $15.00B | -$105.10M | -$143.80M | -$23.96M | -$74.70M |
| Income Before Tax | -$1.01B | -$677.70M | $1.19B | $12.95B | $15.05B | -$145.80M | -$179.40M | -$47.66M | -$85.91M |
| Income Tax Expense | $81.93M | -$12.40M | $255.80M | $3.52B | $4.75B | -$161.00M | -$200,000 | $600,000 | $45,000 |
| Net Income? | -$1.09B | -$665.30M | $930.30M | $9.43B | $10.29B | $15.20M | -$179.10M | -$48.02M | -$85.65M |
| EPS? | $-4.51 | $-2.77 | $3.87 | $38.08 | $43.87 | $0.06 | $-0.85 | $-0.21 | $-0.38 |
| Diluted EPS? | $-4.51 | $-2.77 | $3.83 | $37.09 | $41.21 | $0.06 | $-0.85 | $-0.21 | $-0.38 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality